Combination of PPAR-α Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy

Journal of Diabetes & Metabolism
doi 10.4172/2155-6156.1000320
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Potent Anti-Diabetic Effects of MHY908, a Newly Synthesized PPAR Α/Γ Dual Agonist in Db/Db Mice

PLoS ONE
Multidisciplinary
2013English

Erratum To: DPP-4 Inhibitors in Diabetic Complications: Role of DPP-4 Beyond Glucose Control

Archives of Pharmacal Research
Organic ChemistryDrug DiscoveryMolecular Medicine
2016English

Autophagy as a Therapeutic Target in Diabetic Nephropathy

Experimental Diabetes Research
2012English

Synergistic Antinociception by the Cannabinoid Receptor Agonist Anandamide and the PPAR-α Receptor Agonist GW7647

European Journal of Pharmacology
Pharmacology
2007English

Current Clinical Problems of Diabetic Nephropathy and Novel Approach From Basic Study

Nihon Shoni Jinzobyo Gakkai Zasshi
2014English

DPP-4 Inhibitor-Associated Bullous Pemphigoid in a Hemodialysis Patient

Internal Medicine
Internal MedicineMedicine
2020English

Expert Committee on Novel DPP-4 Inhibitor TRADJENTA (Linagliptin) in Treatment of Type 2 Diabetesmellitus

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Combination Therapy With DPP-4 Inhibitors and Pioglitazone in Type 2 Diabetes: Theoretical Consideration and Therapeutic Potential

Vascular Health and Risk Management
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy